T. Rowe Price Associates
ACIU icon

T. Rowe Price Associates’s AC Immune ACIU Stock Holding History

T. Rowe Price Associates’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-396,919
Closed -$2.66M – 2975
2021
Q3 		$2.66M Buy
+396,919
New +$2.84M ﹤0.01% 1628
2019
Q1 		– Sell
-378,700
Closed -$3.58M – 2530
2018
Q4 		$3.58M Sell
378,700
-700
-0.2% -$6.61K ﹤0.01% 1441
2018
Q3 		$3.04M Buy
+379,400
New +$3.81M ﹤0.01% 1524

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

T. Rowe Price Associates's ACIU Position: Q4 2021 in Review

T. Rowe Price Associates sold out of AC Immune (ACIU) in Q4 2021, closing a stake of 396,919 shares — an estimated $2.66M sold.

T. Rowe Price Associates first reported a position in ACIU in Q3 2018 and held it in 3 quarters. The position peaked at $3.58M in Q4 2018. 44 funds tracked by Wall St. Rank hold ACIU as of Q4 2021.

  • T. Rowe Price Associates reported no remaining AC Immune position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 396,919 AC Immune shares in Q4 2021, an estimated $2.66M.
  • T. Rowe Price Associates first reported a position in AC Immune in Q3 2018 and held it in 3 quarters.
  • T. Rowe Price Associates's AC Immune position peaked at $3.58M in Q4 2018.
  • 44 funds tracked by Wall St. Rank held AC Immune as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.